Amarin Corporation plc

Greetings and welcome to the Ameren Corporation's third quarter 2026 results conference call. At this time all participants are on a listen only mode and a question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. And please note this conference is being recorded. I will now turn the conference over to your host, Mr. Devon Sullivan, Investor Relations. Sir, you may begin.

Thank you for your time and attention this morning as we discuss Ameren's 2026 third quarter financial results. On today's call are Aaron Berg, President and Chief Executive Officer, Pete Fishman, Chief Financial Officer, and Steve Ketchum, President of Research and Development and Chief Scientific Officer. Other members of the senior management team will be available as needed during the Q&A session following the prepared remarks. Aaron will provide a state of the company update. Pete will discuss the numbers and Steve will review recent medical and regulatory activities. Before we begin, I'd like to remind everyone that today's press release and related quarterly report on Form 10Q will be available on the investor relations section of the company's website, www.amroncorp.com, as well as a replay of this call shortly after its completion. Please be aware that during this call, we may make certain statements related to our business that are deemed forward-looking statements under federal securities laws. These statements are not guarantees of future performance, but rather are subject to a variety of risks and uncertainties. Our actual results could differ materially from expectations reflected in any forward-looking statements. Additionally, we assume no obligation to update these statements as circumstances change. For discussion of the material risks and important factors that could affect our actual results, please refer to our SEC filings which are available either on our company website or the Security and Exchange Commission's EDGAR system. With that said, I'd now like to turn the call over to Ameren's President and CEO Aaron Berg. Aaron, please go ahead.

Thanks, Devin, and thank you all for joining us today. As we approach the end of the year, I want to take the opportunity to highlight all that we've achieved, what lies ahead, and most importantly, how we continue to hold ourselves accountable to the standard of delivering value to our shareholders. As you can see in our press release, through the hard work of our team, the support of our commercial partners, and the enduring clinically validated efficacy of the SEPA, the momentum we experienced in the first half of 2026 continued through the third quarter across multiple fronts, including profitable third quarter results, reductions in our expense profile, continued positive operating cash flow, a stronger cash position and zero debt. Our outlook for the full year remains positive. Our partners are expanding the global reach of ASEPA and VASCEPA and driving double digit in market demand growth. We've also maintained our US leadership position in a highly competitive IPE space. We also announced exciting news earlier this week regarding clinical trial results, which may further add to our continued work on broadening our understanding of ASEPA's potential beyond cardiovascular care. And we'll touch on that shortly. As of September 30th, 2026, through our exclusive agreement with Recordati, the SCEPA was commercialized in 11 countries in Europe. And in October, the SCEPA launched in Poland on a private pay basis. In-market demand in Europe for Vescapa under the Recordati partnership rose by an estimated 68% in Q3 2026 compared to the same period last year. Spain, UK, and Italy continue to produce strong results which are helping to build a foundation for future growth as pricing, reimbursement, and commercialization efforts continue across the broader territory. Recordati has been an outstanding partner. While we're still in the early stages of the partnership, their execution and investment are driving momentum materially above historical European growth rates achieved by Ameren prior to the licensing transaction. With the rights to commercialize Vescapa across 59 countries, a deep heritage in cardiovascular disease and extensive commercial capabilities throughout Europe, Recordati is unlocking opportunities beyond our reach in a region with substantial untapped potential. Combined with intellectual property protection through 2039, we have a long runway to create value together. Across our combined global partner network, in-market demand for Vestipa rose by an estimated 55% in Q3 compared to the same period last year, reflecting continued in-market demand growth. were continuing to support our local partners in preparation for launches in Singapore and South Korea in early 2027. And with additional regulatory approvals and market launches across Southeast Asia. We maintained our leading position in the US IPE market with a 47% share while continuing to manage the business profitably. Pricing remains competitive, but our commercial discipline focus and efficiency continue to support our position. We continue to expect to maintain our exclusivity with key payers through the end of 2026 and expect U.S. volumes to remain stable through year end. As background changes in product exclusivity are part of the normal cadence of our U.S. commercial business. At the same time, Our strengthened operating infrastructure gives us greater flexibility to be selective as we evaluate opportunities and elect to move forward only when the economics make sense and support our profitability objectives. I'll now turn the call over to Pete Fishman, our Chief Financial Officer, who will go over our results.